William Blair analyst Matt Larew initiated coverage of Bio-Techne with an Outperform rating. The company is positioned to accelerate its above-market growth in cell and gene therapy through eventual ownership of Wilson Wolf, whose cell culture devices are used in more than 45% of all clinical C> trials, the analyst tells investors in a research note. The firm says Bio-Techne will provide both the “printer” and “ink” of C> trials.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH:
- Bio-Techne ends collaboration with Akoya Biosciences
- Bio-Techne price target lowered to $90 from $100 at Baird
- Bio-Techne reports Q4 adjusted EPS 55c, consensus 55c
- BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2023 RESULTS
- BIO-TECHNE DECLARES DIVIDEND
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue